Efficient screening of cytochrome P450 BM3 mutants for their metabolic activity and diversity toward a wide set of drug-like molecules in chemical space

Drug Metabolism and Disposition

Volumn 39, Issue 9, 2011, Pages 1568-1576

  Reinen, Jelle ^a   Van Leeuwen, Jolanda S ^a   Li, Yongmin ^b   Sun, Lifang ^b   Grootenhuis, Peter D J ^b   Decker, Caroline J ^b   Saunders, John ^b   Vermeulen, Nico P E ^a   Commandeur, Jan N M ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; APREPITANT; ARIPIPRAZOLE; BUSPIRONE; CARBAMAZEPINE; CILOSTAZOL; CINACALCET; CITALOPRAM; CYTOCHROME P450 BM3; DICLOFENAC; DILTIAZEM; DRUG METABOLITE; GLIPIZIDE; HARKOSERIDE; INDOMETACIN; IRBESARTAN; MELOXICAM; MIDAZOLAM; NELFINAVIR; ONDANSETRON; PAROXETINE; PROPAFENONE; REPAGLINIDE; ROSIGLITAZONE; SAQUINAVIR; TERFENADINE; THIORIDAZINE; UNINDEXED DRUG; VERAPAMIL;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG SCREENING; ENZYME ACTIVITY; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MASS SPECTROMETRY; MOLECULAR WEIGHT; MUTANT; PHENOTYPE; PRIORITY JOURNAL; STEREOCHEMISTRY;

BACTERIAL PROTEINS; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; GENE LIBRARY; HUMANS; MASS SPECTROMETRY; METABOLIC DETOXICATION, DRUG; MICROSOMES, LIVER; MUTAGENESIS, SITE-DIRECTED; PHARMACEUTICAL PREPARATIONS; SUBSTRATE SPECIFICITY;

BACTERIA (MICROORGANISMS);

EID: 80052010909     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.039461     Document Type: Article

References (37)

1. Appel D., Lutz-Wahl S., Fischer P., Schwaneberg U, and Schmid R.D. (2001) A P450 BM- 3 mutant hydroxylates alkanes, cycloalkanes, arenes and heteroarenes. J Biotechnol 88:167-171. (Pubitemid 32524253)
2. Bernhardt R. (2006) Cytochromes P450 as versatile biocatalysts. J Biotechnol 124:128-145.
3. Carmichael AB and Wong L.L. (2001) Protein engineering of Bacillus megaterium CYP102. The oxidation of polycyclic aromatic hydrocarbons. Eur J Biochem 268:3117-3125. (Pubitemid 32862999)
4. Chefson A and Auclair K. (2006) Progress towards the easier use of P450 enzymes. Mol Biosyst 2:462-469. (Pubitemid 44433803)
5. Damsten M.C., De Vlieger J.S., Niessen W.M., Irth H., Vermeulen NP, and Commandeur J.N. (2008a) Trimethoprim: Novel reactive intermediates and bioactivation pathways by cytochrome P450s. Chem Res Toxicol 21:2181-2187.
6. Damsten M.C., Van Vugt-Lussenburg B.M., Zeldenthuis T., De Vlieger J.S., Commandeur JN, and Vermeulen N.P. (2008b) Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites. Chem Biol Interact 171:96-107. (Pubitemid 350191849)
7. Dietrich M., Do T.A., Schmid R.D., Pleiss J, and Urlacher V.B. (2009) Altering the regioselectivity of the subterminal fatty Acid hydroxylase P450 BM- 3 towards gamma- 3 towards gammaAnd delta- 3 towards gammaAnd deltaPositions. J Biotechnol 139:115-117.
8. Fasan R., Chen M.M., Crook NC, and Arnold F.H. (2007) Engineered alkane- Hydroxylating cytochrome P450(BM3) exhibiting nativelike catalytic properties. Angew Chem Int Ed Engl 46:8414-8418. (Pubitemid 350114951)
9. Guengerich F.P., Gillam EM, and Shimada T. (1996) New applications of bacterial systems to problems in toxicology. Crit Rev Toxicol 26:551-583. (Pubitemid 26343226)
10. Kim D.H., Ahn T., Jung H.C., Pan JG, and Yun C.H. (2009) Generation of the human metabolite piceatannol from the anticancer-preventive agent resveratrol by bacterial cytochrome P450 BM3. Drug Metab Dispos 37:932-936.
11. Kim D.H., Kim K.H., Kim D.H., Liu K.H., Jung H.C., Pan JG, and Yun C.H. (2008) Generation of human metabolites of 7-ethoxycoumarin by bacterial cytochrome P450 BM3. Drug Metab Dispos 36:2166-2170.
12. Kim K.H., Kang J.Y., Kim D.H., Park S.H., Park S.H., Kim D., Park K.D., Lee Y.J., Jung H.C., Pan J.G., et al. (2011) Generation of human chiral metabolites of simvastatin and lovastatin by bacterial CYP102A1 mutants. Drug Metab Dispos 39:140-150.
13. Kubo T., Peters M.W., Meinhold P, and Arnold F.H. (2006) Enantioselective epoxidation of terminal alkenes to (R)- And (S)- And (S)Epoxides by engineered cytochromes P450 BM-3. Chemistry 12:1216-1220. (Pubitemid 43145167)
14. Kumar S and Halpert J.R. (2005) Use of directed evolution of mammalian cytochromes P450 for investigating the molecular basis of enzyme function and generating novel biocatalysts. Biochem Biophys Res Commun 338:456-464. (Pubitemid 41540590)
15. Landwehr M., Hochrein L., Otey C.R., Kasrayan A., Bäckvall JE, and Arnold F.H. (2006) Enantioselective alpha-hydroxylation of 2-arylacetic acid derivatives and buspirone catalyzed by engineered cytochrome P450 BM-3. J Am Chem Soc 128:6058-6059.
16. Li H and Poulos T.L. (1997) The structure of the cytochrome P450BM- 3 haem domain complexed with the fatty acid substrate, palmitoleic acid. Nat Struct Biol 4:140-146. (Pubitemid 27066389)
17. Li Q.S., Ogawa J., Schmid RD, and Shimizu S. (2001a) Engineering cytochrome P450 BM- 3 for oxidation of polycyclic aromatic hydrocarbons. Appl Environ Microbiol 67:5735-5739. (Pubitemid 33641012)
18. Li Q.S., Schwaneberg U., Fischer M., Schmitt J., Pleiss J., Lutz-Wahl S, and Schmid R.D. (2001b) Rational evolution of a medium chain- Specific cytochrome P-450 BM- Specific cytochrome P450 BM3 variant. Biochim Biophys Acta 1545:114-121. (Pubitemid 32124813)
19. Li Q.S., Schwaneberg U., Fischer P, and Schmid R.D. (2000) Directed evolution of the fatty-acid hydroxylase P450 BM-3 into an indoleHydroxylating catalyst. Chemistry 6:1531-1536.
20. Lussenburg B.M., Babel L.C., Vermeulen NP, and Commandeur J.N. (2005) Evaluation of alkoxyresorufins as fluorescent substrates for cytochrome P450 BM3 and site- Directed mutants. Anal Biochem 341:148-155. (Pubitemid 40615731)
21. Manallack D.T. (2008) The pK(a) distribution of drugs: Application to drug discovery. Perspect Medicin Chem 1:25-38.
22. Munro A.W., Leys D.G., McLean K.J., Marshall K.R., Ost T.W., Daff S., Miles C.S., Chapman S.K., Lysek D.A., Moser C.C., et al. (2002) P450 BM3: The very model of a modern flavocytochrome. Trends Biochem Sci 27:250-257. (Pubitemid 34655446)
23. Munzer D.F., Meinhold P., Peters M.W., Feichtenhofer S., Griengl H., Arnold F.H., Glieder A, and De Raadt A. (2005) Stereoselective hydroxylation of an achiral cyclopentanecarboxylic acid derivative using engineered P450s BM-3. Chem Commun (Camb) 20:2597-2599. (Pubitemid 40825256)
24. Narhi LO and Fulco A.J. (1986) Characterization of a catalytically self- Sufficient 119,000- Sufficient 119,000Dalton cytochrome P- Sufficient 119,000Dalton cytochrome P450 monooxygenase induced by barbiturates in Bacillus megaterium. J Biol Chem 261:7160-7169. (Pubitemid 17224707)
25. Otey C.R., Bandara G., Lalonde J., Takahashi K, and Arnold F.H. (2006) Preparation of human metabolites of propranolol using laboratory- Evolved bacterial cytochromes P450. Biotechnol Bioeng 93:494-499. (Pubitemid 43232175)
26. Peters M.W., Meinhold P., Glieder A, and Arnold F.H. (2003) Regio- And enantioselective alkane hydroxylation with engineered cytochromes P450 BM-3. J Am Chem Soc 125:13442-13450. (Pubitemid 37352128)
27. Rentmeister A., Arnold FH, and Fasan R. (2009) Chemo-enzymatic fluorination of unactivated organic compounds. Nat Chem Biol 5:26-28.
28. Sawayama A.M., Chen M.M., Kulanthaivel P., Kuo M.S., Hemmerle H, and Arnold F.H. (2009) A panel of cytochrome P450 BM3 variants to produce drug metabolites and diversify lead compounds. Chemistry 15:11723-11729.
29. Schroer K., Kittelmann M, and Lütz S. (2010) Recombinant human cytochrome P450 monooxygenases for drug metabolite synthesis. Biotechnol Bioeng 106:699-706.
30. Seifert A., Vomund S., Grohmann K., Kriening S., Urlacher V.B., Laschat S, and Pleiss J. (2009) Rational design of a minimal and highly enriched CYP102A1 mutant library with improved regio- , stereo- , stereoAnd chemoselectivity. Chembiochem 10:853-861.
31. Smith DA and Obach R.S. (2009) Metabolites in safety testing (MIST): Considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem Res Toxicol 22:267-279.
32. Stjernschantz E., Van Vugt-Lussenburg B.M., Bonifacio A., De Beer S.B., Van der Zwan G., Gooijer C., Commandeur J.N., Vermeulen NP, and Oostenbrink C. (2008) Structural rationalization of novel drug metabolizing mutants of cytochrome P450 BM3. Proteins 71:336-352. (Pubitemid 351358614)
33. Tartof KD and Hobbs C.A. (1988) New cloning vectors and techniques for easy and rapid restriction mapping. Gene 67:169-182.
34. Van Vugt-Lussenburg B.M., Damsten M.C., Maasdijk D.M., Vermeulen NP, and Commandeur J.N. (2006) Heterotropic and homotropic cooperativity by a drug-metabolising mutant of cytochrome P450 BM3. Biochem Biophys Res Commun 346:810-818.
35. Van Vugt-Lussenburg B.M., Stjernschantz E., Lastdrager J., Oostenbrink C., Vermeulen NP, and Commandeur J.N. (2007) Identification of critical residues in novel drug metabolizing mutants of cytochrome P450 BM3 using random mutagenesis. J Med Chem 50:455-461. (Pubitemid 46239780)
36. Whitehouse C.J., Bell S.G., Tufton H.G., Kenny R.J., Ogilvie LC, and Wong L.L. (2008) Evolved CYP102A1 (P450BM3) variants oxidise a range of non- Natural substrates and offer new selectivity options. Chem Commun (Camb) 8:966-968. (Pubitemid 351281049)
37. Zanger U.M., Turpeinen M., Klein K, and Schwab M. (2008) Functional pharmacogenetics/ genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 392:1093-1108.